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Introduction: There is a strong evidence that tumour growth is not just a 
consequence of uncontrolled proliferation but also of reduced apoptosis. Bax and Bcl-2 
are Bcl-2 family like apoptosis regulator. They function either as suppressor (Bcl-2) or a 
promoter (Bax) of apoptosis. As a member of the inhibitors of apoptosis (IAP), survivin 
is also a promoter of cellular proliferation and thus a key player in cancer progression. 
Beside, caspases also occupy a central role in maintaining cellular homeostasis.   
Objectives: Therefore, this research aims to examine the apoptotic effects of 
Rapamycin and Platelet Factor 4 (PF4) on 1-methyl-1-nitrosourea (MNU)-induced 
mammary carcinoma through Bcl-2- survivin and caspase modulated pathways in female 
Sprague Dawley Rat (SDR) and in vitro MCF-7 breast cancer cell lines.  
Methods: One hundred 21 days old female SDR were given an intraperitoneal 
injection (IP) of MNU to induce breast cancer formation. When tumour size reached 
14.5±0.5mm, intratumoural injections of the following interventions were given; Group 1 
(pre-intervention control, n=20 and post-intervention control, n=20), Group 2 
(Rapamycin-treated, n=20), Group 3 (PF4-treated, n=20) and Group 4 (Rapamycin+PF4-
treated, n=20). Tumour growth was then morphologically assessed using haematoxylin 
and eosin (H&E) and immunohistochemistry (IHC) utilizing pro-apoptosis (Bax) and 
anti-apoptosis markers (Bcl-2), survivin and caspases-3,-6,-7,-8, and -9. Besides that, the 
MCF-7 cell line was used for in vitro assessment. Initially, half maximal inhibitory 
concentration (IC50) of each drug was determined. The MCF-7 cell lines were then 
exposed to Rapamycin and PF4 and Rapammycin+PF4 at IC50 concentrations, after 
which they were subjected to flow cytometry and Western blot analyses. 
Results: Bax was significantly expressed at higher levels in the rapamycin-treated 
and Rapamycin+PF4-treated groups than controls (p<0.001). Besides, survivin was 
significantly downregulated in the PF4-treated and Rapamycin+PF4-treated group when 
compared to controls (p<0.001). On the other hand, Bcl-2 expression was found not to be 
significantly altred in all treatment groups. Caspase-3, was significantly expressed at 
higher levels in both PF4-treated and Rapamycin+PF4-treated groups than controls 
(p<0.001), as well as rapamycin-only group when compared to Rapamycin+PF4-treated 
and PF4-treated groups (both p<0.001). Apart from that, caspase-6 was also significantly 
expressed in Rapamycin-treated, PF4-treated and Rapamycin+PF4-treated than the 
control groups (p<0.001). Besides, either PF4 or Rapamycin+PF4 combination was 
associated with increased caspase-7 expression, compared to the controls (p<0.001). 
However, Rapamycin-treated group showed a significantly higher caspase-8 expression 
when compared to PF4-treated (p<0.05). For caspase-9, higher caspase-9 expression was 
observed in Rapamycin-treated group when compared to control, Rapamycin+PF4-
treated and PF4-treated cohorts (p<0.001). The IC50 Rapamycin, PF4 and 
Rapamycin+PF4 were 0.4 µg/ml, 6 µg/ml and 0.4 µg/ml+1.0 µg/ml respectively. 
Rapamycin and PF4, on the other hand, were non-toxic to the normal HMEC cells. 
Furthermore, Rapamycin, PF4 and Rapamycin+PF4 induced a cell cycle arrest in MCF-7 
cell lines at G0/G1, S and G0/G1 phases, respectively. Rapamycin, PF4 and 
Rapamycin+PF4 induced the upregulation of pro-apoptotic Bax and the downregulation 
of anti-apoptotic Bcl-2 and survivin. The expression levels of caspase-3 and caspase-8 
were consistent  in the treated group when compared with the control group. The 
expression of caspases -6, -7 and -9 protein were increased when treated with 
Rapamycin, Rapamycin + PF4 and PF4 when compared with the control group.  
Conclusion, this study provides new insights on the mechanistic properties of 
Rapamycin and PF4 as anti-cancer agents in breast cancer animal model and in vitro 
MCF-7 cell lines.  The results lend support to the notion that apoptotic induction by 
Rapamycin and PF4 and was mediated by both the intrinsic and extrinsic pathways 
through the activation of caspase-9, caspase-3 and caspase-8 activation.  
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expression (brown colour) in tumour specimens in  
Rapamycin+PF4 groups (IHC, original magnification 
x100). 
 
(B) Histological section showing positive caspase-3 
expression (brown colour) in tumour specimens of control 
groups (IHC, original magnification x100). 
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Plate 3.6 (A) Histological section showing caspase-6 positive 
expression (brown colour) in tumour of  Rapamycin (IHC, 
original magnification x100). 
(B) Histological section showing caspase-6 positive 
expression (brown colour) in tumour of control groups 
(IHC, original magnification x100). 
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Plate 3.7 (A) Histological section showing caspase-7 positive 
expression (brown colour) in tumour of  PF4 groups (IHC, 
original magnification x100).) 
(B) Histological section showing caspase-7 positive 
expression  (brown  colour)  in tumour of  control groups 
(IHC, original magnification x100). 
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Plate 3.8 (A) Histological section showing caspase-8 positive 
expression (brown colour) in tumour of PF4  groups (IHC, 
original magnification x100).  
(B) Histological section showing caspase-8 positive 
expression (brown colour) in tumour of  control groups 
(IHC, original magnification x100).  
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Plate 3.9 (A) Histological section showing caspase-9 positive 
expression (brown colour) in tumour of  PF4 groups (IHC, 
original magnification x100). 
(B) Histological section showing caspase-9 positive 
expression (brown colour)   in tumour of  control groups  
(IHC, original magnification x100). 
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Plate 3.10 
The morphology of the cells were not affected upon 
treatment with Rapamycin, PF4 and Rapamycin+PF4 when 
compared with HMEC untreated control cells. This showed 
that Rapamycin, PF4 and Rapamycin+PF4 causes no toxic 
on HMEC and can be considered as safe to be used on 
normal cells.  
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Plate 3.11 Reduced cell number and morphological changes at 
different magnification after 72 hours. The cells were 
treated with Rapamycin, PF4 and Rapamycin+PF4 at IC50 
and were observed under inverted phase contrast 
microscope. The untreated cells (a) were homogenously 
distributed with polygonal shapes, distinct boundaries and 
homogenous cellular contents. On the contrary, the number 
of cells were reduced upon treatment with Rapamycin, PF4 
and Rapamycin+PF4 at each IC50 (b-d), with obvious loss 
of characteristic appearance, became rounded and 
subsequently detached from the culture surface, indicating 
that the cell growth had been successfully inhibited. 
136 
Plate 3.12 Effect of Rapamycin, PF4 and Rapamycin+PF4 on MCF-7 
cells indicating apoptotic-related features. The cells were 
treated with IC50 of Rapamycin, PF4 and Rapamycin+PF4 
at 72hours and observed under phase contrast inverted 
microscope (magnification 100x). Red arrows show of 
Rapamycin, PF4 and Rapamycin+PF4 treated cell with the 
presence of: a-Apoptotic bodies; b-irregular shapes; c-
Condensed nuclei and d-cell elongation 
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KEBERKESANAN RAPAMYCIN DAN PF4 PADA MODEL HAIWAN 
INDUKSI MNU KANSER PAYUDARA DAN TITISAN SEL KANSER 
(MCF-7) 
ABSTRAK 
Terdapat bukti yang kukuh bahawa pertumbuhan tumor bukan sahaja akibat 
daripada proliferasi yang tidak terkawal tetapi juga apoptosis dikurangkan. Bax dan 
Bcl-2 adalah protein keluarga Bcl-2 yang mengawal proses apoptosis. Ia berfungsi 
sama ada sebagai anti-apoptosis (Bcl-2) atau pro-apoptosis (Bax). Perencat apoptosis 
(IAP), survivin juga sebagai anti-apoptotik, dimana ia mempromosi proliferasi sel dan  
memainkan peranan utama dalam perkembangan kanser. Disamping itu, caspase juga 
memainkan peranan penting untuk mengekalkan homeostasis sel. Oleh itu, kajian ini 
bertujuan untuk mengkaji kesan apapotik Rapamycin dan Platelet Faktor 4 (PF4) ke 
atas model kajian kanser payudara tikus betina melalui induksi 1-metil-1-nitrosourea 
(MNU) yang karsinogenik dan dalam titisan sel kanser MCF-7. Tindak balas ini 
seterusnya melihat kepada kesan laluan ekpresi keluarga Bcl-2,  survivin dan keluarga 
caspase. Sebanyak seratus ekor tikus betina (SDR), berumur 21 hari diberikan MNU 
secara suntikan intraperitroneum (IP) untuk merangsang pembentukan kanser 
payudara. Apabila tumor mencapai saiz  14.5±0.5 mm, model tikus tersebut 
dibahagikan kepada beberapa kumpulan mengikut jenis rawatan yang diberikan 
seperti berikut; Kumpulan 1  (pra-intervensi, n=20 dan selepas intervensi, n=20), 
Kumpulan 2 (rapamycin, n=20),  Kumpulan 3 (PF4, n=20) dan Kumpulan 4 
(rapamycin+PF4, n=20). Perubahan morfologi tumor kemudian dinilai dengan 
menggunakan pewarna hematoksilin eosin (H&E) serta imunohistokimia (IHC) 
dengan menggunakan penanda pro-apoptosis (Bax), anti-apoptosis (Bcl-2), survivin 
 xxviii 
 
dan caspase-3, -6, -7, -8 dan -9. Di samping itu, MCF-7 telah digunakan untuk 
analisis secara in vitro. Kemudian MCF-7  diteruskan untuk analisis menggunakan 
sitometri aliran dan pemendapan western. Didapati bahawa taburan ekpresi Bax 
meningkat dengan tinggi dalam kumpulan yang dirawat dengan Rapamycin secara 
sangat signifikan (p<0.001) dan Rapamycin+PF4 secara signifikan (p=0.007) apabila 
dibandingkan dengan kontrol. Selain itu, ekpresi survivin menunjukkan penurunan 
yang sangat signifikan dalam kumpulan yang dirawat dengan PF4 dan 
Rapamycin+PF4 apabila dibandingkan dengan kontrol (p<0.001). Sebaliknya, 
ekspresi Bcl-2 didapati tidak berbeza dengan ketara dalam semua kumpulan rawatan. 
Caspase-3 menunjukkan ekspresi yang sangat signifikan dalam kumpulan yang 
dirawat dengan PF4 dan Rapamycin+PF4 secara sangat signifikan (p<0.001) apabila 
dibandingkan dengan kontrol dan juga kumpulan yang dirawat dengan rapamycin 
sahaja apabila dibandingkan dengan Rapamycin+PF4 dan  kumpulan PF4  (masing-
masing p<0.001). Selain itu, ekspresi caspase-6 menunjukkan taburan yang sangat 
signifikan dalam kumpulan rawatan Rapamycin, PF4 dan Rapamycin+PF4 apabila 
dibandingkan dengan kumpulan control (p<0.001). Selain itu, ekspresi caspase-7 
menunjukkan ekspresi yang sangat signifikan dalam kumpulan yang dirawat sama ada 
dengan  PF4 atau Rapamycin+PF4 apabila dibandingkan dengan kontrol (p<0.001). 
Walau bagaimanapun, kumpulan Rapamycin sahaja menunjukkan ekspresi caspase-8 
yang lebih tinggi apabila dibandingkan dengan PF4 (p<0.05). Manakala ekspresi 
caspase-9  menunjukkan ekspresi yang signifikan (p<0.05) dalam kumpulan 
Rapamycin sahaja berbanding dengan kontrol dan Rapamycin+PF4 dan PF4 dirawat 
kohort (p <0.001). Rapamycin, PF4 dan Rapamycin+PF4 menunjukkan kesan 
perencatan pada  IC50 0.4 μg/ml,    6 μg/ml dan 0.4+1.0 μg/ml masing-masing. 
Rapamycin dan PF4, pada masa yang sama juga telah didapati tidak toksik kepada sel 
 xxix 
 
HMEC. Tambahan pula, rapamycin, PF4 dan Rapamycin+PF4 menyebabkan 
gangguan kitaran sel di G0/G1, S dan G0/G1,  masing-masing. Rapamycin, PF4 dan 
Rapamycin+PF4 mendorong peningkatan paras protein pro-apoptotik Bax dan 
penurunan paras protein anti-apoptotik Bcl-2 dan survivin. Paras protein caspases-3 
dan caspase-8 konsisten dalam kumpulan yang dirawat apabila dibandingkan dengan 
kumpulan kontrol. Manakala paras protein -6, -7 dan -9 didapati telah meningkat 
apabila dirawat dengan Rapamycin, PF4 dan Rapamycin+PF4 apabila dibandingkan 
dengan kumpulan kontrol. Kesimpulan, kajian ini telah menemui hasilan baru tentang 
sifat mekanistik Rapamycin, PF4 dan Rapamycin+PF4 sebagai agen anti-kanser 
dalam kanser payudara model haiwan in vivo dan in vitro, MCF-7-bahagian sel. 
Pengenal pastian laluan isyarat kemungkinan melibatkan kematian sel secara 
apoptosis telah mengakibatkan gangguan kitaran sel  telah dibuktikan sehingga ke 
peringkat molekular. Keputusan ini telah disokong melalui  induksi apoptotik oleh 
Rapamycin, PF4 dan Rapamycin+PF4 yang mengaktifkan kedua-dua laluan intrinsik 
dan ekstrinsik melalui pengaktifan caspase-9, caspase-3 dan caspase-8. Selain itu, 
rawatan Rapamycin, PF4 dan Rapamycin+PF4 juga boleh merencatkan pertumbuhan 
kanser payudara dan mendorong apoptosis melalui caspase yang bergantung kepada 
laluan mitokondria dan mungkin menyebabkan kerosakan DNA. 
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ELUCIDATING THE EFFECTS OF RAPAMYCIN AND PF4 ON THE MNU 
INDUCED FEMALE RATS AND HUMAN BREAST CANCER CELLS 
(MCF-7) 
 
                                ABSTRACT 
There is a strong evidence that tumour growth is not just a consequence of 
uncontrolled proliferation but also of reduced apoptosis. Bax and Bcl-2 are Bcl-2 
family like apoptosis regulator. They function either as suppressor (Bcl-2) or a 
promoter (Bax) of apoptosis. As a member of the inhibitors of apoptosis (IAP), 
survivin is also a promoter of cellular proliferation and thus a key player in cancer 
progression. Beside, caspases also occupy a central role in maintaining cellular 
homeostasis.  Therefore, this research aims to examine the apoptotic effects of 
Rapamycin and Platelet Factor 4 (PF4) on 1-methyl-1-nitrosourea (MNU)-induced 
mammary carcinoma through Bcl-2- survivin and caspase modulated pathways in 
female Sprague Dawley Rat (SDR) and in vitro MCF-7 breast cancer cell lines. One 
hundred 21 days old female SDR were given an intraperitoneal injection (IP) of MNU 
to induce breast cancer formation. When tumour size reached 14.5±0.5mm, 
intratumoural injections of the following interventions were given; Group 1 (pre-
intervention control, n=20 and post-intervention control, n=20), Group 2 (Rapamycin-
treated, n=20), Group 3 (PF4-treated, n=20) and Group 4 (Rapamycin+PF4-treated, 
n=20). Tumour growth was then morphologically assessed using haematoxylin and 
eosin (H&E) and immunohistochemistry (IHC) utilizing pro-apoptosis (Bax) and anti-
apoptosis markers (Bcl-2), survivin and caspases-3,-6,-7,-8, and -9. Besides that, the 
MCF-7 cell line was used for in vitro assessment. Initially, half maximal inhibitory 
concentration (IC50) of each drug was determined. The MCF-7 cell lines were then 
exposed to Rapamycin and PF4 and Rapammycin+PF4 at IC50 concentrations, after 
 xxxi 
 
which they were subjected to flow cytometry and Western blot analyses. Bax was 
significantly expressed at higher levels in the rapamycin-treated and Rapamycin+PF4-
treated groups than controls (p<0.001). Besides, survivin was significantly 
downregulated in the PF4-treated and Rapamycin+PF4-treated group when compared 
to controls (p<0.001). On the other hand, Bcl-2 expression was found not to be 
significantly altred in all treatment groups. Caspase-3, was significantly expressed at 
higher levels in both PF4-treated and Rapamycin+PF4-treated groups than controls 
(p<0.001), as well as rapamycin-only group when compared to Rapamycin+PF4-
treated and PF4-treated groups (both p<0.001). Apart from that, caspase-6 was also 
significantly expressed in Rapamycin-treated, PF4-treated and Rapamycin+PF4-
treated than the control groups (p<0.001). Besides, either PF4 or Rapamycin+PF4 
combination was associated with increased caspase-7 expression, compared to the 
controls (p<0.001). However, Rapamycin-treated group showed a significantly higher 
caspase-8 expression when compared to PF4-treated (p<0.05). For caspase-9, higher 
caspase-9 expression was observed in Rapamycin-treated group when compared to 
control, Rapamycin+PF4-treated and PF4-treated cohorts (p<0.001). The IC50 
Rapamycin, PF4 and Rapamycin+PF4 were 0.4 µg/ml, 6 µg/ml and 0.4 µg/ml+1.0 
µg/ml respectively. Rapamycin and PF4, on the other hand, were non-toxic to the 
normal HMEC cells. Furthermore, Rapamycin, PF4 and Rapamycin+PF4 induced a 
cell cycle arrest in MCF-7 cell lines at G0/G1, S and G0/G1 phases, respectively. 
Rapamycin, PF4 and Rapamycin+PF4 induced the upregulation of pro-apoptotic Bax 
and the downregulation of anti-apoptotic Bcl-2 and survivin. The expression levels of 
caspase-3 and caspase-8 were consistent  in the treated group when compared with the 
control group. The expression of caspases -6, -7 and -9 protein were increased when 
treated with Rapamycin, Rapamycin + PF4 and PF4 when compared with the control 
 xxxii 
 
group. In conclusion, this study provides new insights on the mechanistic properties 
of Rapamycin and PF4 as anti-cancer agents in breast cancer animal model and in 
vitro MCF-7 cell lines.  The results lend support to the notion that apoptotic induction 
by Rapamycin and PF4 and was mediated by both the intrinsic and extrinsic pathways 
through the activation of caspase-9, caspase-3 and caspase-8 activation.  
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CHAPTER 1 
                INTRODUCTION 
1.1 Overview On Breast Cancer 
Breast cancer is the commonest malignancy in women and the second leading 
cause of cancer deaths. The latest 2012 report on the incidence and mortality  from 
breast cancer showed that  226,870 new cases of invasive breast cancer and 39,510 
breast cancer deaths are expected to arise among U.S. women (Ma & Jemal, 2013). 
On the other hand, the incidence and mortality of breast cancer rates over the past 
20 years have sharply increased in economically less developed regions. Based on 
the GLOBOCAN report in 2008, it was estimated that half of the new worldwide 
breast cancer cases (1.38 million) and 60 % of the breast cancer deaths (458,000) 
occurred in developing countries (GLOBOCAN 2008 (IARC) 2008). Besides that, 
new data published by the National Cancer Institute in 2013 demonstrated that the 
number of new cases and death from breast cancer among women in the United 
States were 232,340 and 2,240, respectively. Based on this data the number of breast 
cancer cases is on the ascendancy. 
As in Malaysia, breast cancer is the most common cancer in women because  
probably because men have less of the female hormones estrogen and progesterone, 
which can promote breast cancer cell growth. About 3,242 cases of breast cancer 
were diagnosed in women in 2007, contributing 18.1% of all reported cancer cases 
and 32.1% of total cancer cases in  women (National Cancer Registry Report 2007).  
It has predilection for all major ethnic groups which include Malays, Chinese and 
Indians (Yip et al., 2006). 
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1.2 About The Breast  
The breast is generally made up of fatty tissue. This tissue consists a set of 
network of lobes, which are composed of tiny, tube-like structures called lobules that 
houses milk glands (Azordegan et al., 2013; Rees & Bath, 2000). Tiny ducts fix the 
glands, lobules and lobes, carrying the milk from the lobes to the nipple, which is 
positioned at the middle of the areola (the darker spot that surrounds the nipple) 
(Figure 1.1). Blood and lymphatic vessels also run throughout the breast; blood 
nourishes the cells and the lymphatic channels drain physical waste products (Heys, 
2011; Tse et al., 2013). The lymphatic vessels connect to lymph nodes, the tiny, 
bean-shaped organs that play paramount roles in immunological defense against 
infections. 
 
The mammary glands of mammalians are unique since it evolved into an 
organ that is specialized in synthesizing, secreting, and distributing milk to the 
newborns which is critical for their optimal nutrients, protection, and development 
(Nguyen et al., 2011). In humans, the female mammary gland lifespan is 
characterized by harsh changes in architecture, composition, and functionality, 
mediated by obvious changes in gene appearance, that distinguishes its physiological 
stages of development, all of which are intended at allowing it to perform its function 
as a milk-producing organ upon the birth of the infant (Hassiotou & Geddes, 2013). 
The key developmental milestones of mammary glands consist of fetal growth, 
pubertal expansion, infant (pre-pubertal) growth, lactation and pregnancy associated 
remodeling, and post-lactation and post-menopausal involution (Hassiotou & 
Geddes, 2013). A vital  knowledge on the anatomy, development, physiology, and 
regulation of the breast is important in the understanding of both the normal biology 
 3 
 
and function of this organ and its benign or malignant pathologies which may ensure 
a successful implementation of relevant treatments on each malady.  
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Anatomy of the breast and chest wall (Heys, 2011). 
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1.3 Breast Cancer Pathogenesis 
Cancer exists as a result of mutations, or abnormal changes, in the genes 
responsible for regulating cellular growth and its physiological maintenance 
(Børresen-Dale et al., 2010; Voduc et al., 2010). The genes are in each cell’s nucleus, 
which acts as the “control room” of each cell. Generally, the cells in human bodies 
restore themselves through an orderly process of cell growth: healthy new cells take 
over as old ones senesced and withered (Weigelt et al., 2010). However, as time goes 
by, mutations can activate certain genes and deactivate others in a cell. That 
genetically-altered cell gains the ability to keep proliferating in such a disorderly 
fashion, producing identical daughter cells which eventually culminate in the 
formation of a tumour (Weinberg, 2013).  
 
There are two types of tumour; benign (not dangerous to health) and 
malignant (has the potential to be dangerous) (Bhattarai et al., 2011). The benign 
tumours are considered non-cancerous: their cells are genetically and 
morphologically similar to the normal ones; they grow much gradually and do not 
invade adjacent tissues or disseminates to the other parts of the body (Kennecke et 
al., 2010; Liu et al., 2011). Malignant tumours are, on the contrary, cancerous. Left 
unchecked, malignant cells can ultimately spread beyond the tumuor’s primary site 
to other organs in the body (Chang et al., 2011; Kennecke et al., 2010). 
 
Breast cancer therefore refers to any malignant tumour that originates from 
normal mammary cells (Bombonati & Sgroi, 2011; Chang et al., 2011). Generally, 
breast cancer either begins in the cells of the lobules, which are the milk-producing 
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glands, or the ducts, the passages that drain milk from the lobules to the nipple 
(Bombonati & Sgroi, 2011; Rakha et al., 2006). Less commonly, breast cancer may 
also begin in the stromal tissues, which include the fatty and fibrous connective 
tissues of the breast (Fentiman & D'Arrigo, 2004; Voduc et al., 2010). 
 
 Breast cancer can be classified into biologically and clinically different 
entities according to its histological type (Santagata et al., 2014) and histological 
grades, both carry different prognostic values (Horlings et al., 2013; Santagata et al., 
2014). Tumour grade is measured by the degree of histological and cytological 
differentiation (i.e. tubule formation and nuclear pleomorphism) and the proliferative 
potential (i.e. mitotic index) of the tumour, both reflect its aggressiveness (Dinkel et 
al., 2000).  It has also been included as one of the prognostic determinants in various 
validated prognostic staging systems such as the Nottingham Prognostic Index and 
Adjuvant! Online, from which the accurate tailoring of breast cancer treatment can 
be made possible (Horlings et al., 2013; Narbe et al., 2014). Interestingly, breast 
cancer histological grade has been shown to correlate well with its genetic and 
transcriptomic features and these observation has led to the devising of microarray-
based genomic signatures which are useful for prognostic and research purposes  
(Garcia-Closas et al., 2013; Horlings et al., 2013). 
 
Contrarily,  histological type of breast cancer  refers to the tumour growth 
patterns (Horlings et al., 2013). Pathologist has long been fascinated with the 
histological diversity of breast cancers and they have identified specific cytological 
and morphological patterns that are consistently and well associated with the 
spectrum clinical presentations. The most common type of breast carcinoma is 
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invasive ductal carcinomas not otherwise specified (IDC-NOS) or of no special type 
(IDC-NST) (Narbe et al., 2014; Weigelt et al., 2010) which is diagnosed by  
exclusion and comprises of adenocarcinomas that are devoid of any adequate 
histological characteristics that may allow them to be classified as one of the specific 
subtypes of breast cancers (Lacroix‐Triki et al., 2010).  
 
Specific types of breast cancer account for up to 25% of all breast cancer 
cases and in the latest edition of the World Health Organization classification for 
breast cancer recognizes the existence of at least 17 distinct histological special types 
(Lacroix‐Triki et al., 2010). It is worth noted that information on tumour grade and 
type supplement each other (Bombonati & Sgroi, 2011). Even though grade 
identifies prognostic subgroups among special types of breast cancer, some 
histological types of breast cancer that are made of poorly differentiated cells (high 
histological grade)  may have a relatively good prognosis (e.g. medullary 
carcinomas) (Dinkel et al., 2000; Huober et al., 2012). 
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1.4 Morphogenesis of Normal Mammary Gland 
Mammary glands are epidermal appendages that are hypothetically developed 
from the evolutionarily-ancient apocrine glands which were connected to the skin 
(Hens & Wysolmerski, 2005). The major function of the mammary gland is to supply 
nutrition for the young in the form of milk fat and protein (Kent et al., 2013; Tiede & 
Kang, 2011). Apart from that, there are other benefits that are provided by lactation, 
for instance the provision of immune factors that are secreted into the milk and the 
nurturing of mother-infant during breastfeeding might confer developmental benefits 
to the newborns (Noel-Weiss et al., 2010). The mammary gland is a unique secretory 
organ that consists of a number of dissimilar cell types: epithelial cells that form the 
ductal network of the gland; adipocytes, which comprise the fat pad and in which the 
ductal network is implanted; vascular endothelial cells, which make up the blood 
vessels; stromal cells, including fibroblasts; and a variety of immune cells (Howlin et 
al., 2006). The mammary gland consists of two main epithelial types: luminal and 
basal (Sopel, 2010). The basal epithelium consists of myoepithelial cells, whereas 
luminal epithelium forms the ducts and the secretory alveoli (Sopel, 2010; Van 
Keymeulen et al., 2011). These two types of epithelium form a bi-layered structure 
of simple epithelium that is surrounded by the fatty stroma (Sakakura et al., 2013; 
Sopel, 2010). 
 
There are three main steps of mammary gland development, both in rodents 
and humans: embryonic, pubertal and adult (Van Keymeulen et al., 2011). Growth 
factors and hormones play fundamental roles in these different steps of normal 
mammary development and its antipode, breast cancer (Brisken & O’Malley, 2010). 
The mammary gland is an ideal tissue to study human developmental processes. In 
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the embryo, the cellular signaling pathways that stimulate/induce the formation of 
mammary placodes from the skin are yet to be fully elucidated (Sakakura et al., 
2013). Besides that, similar mechanistic pathways have also been discovered in the 
developing stages of other anatomical appendages, such as teeth and feathers 
(Forsmanl & Schwertfegerz, 2013), suggesting the crucial role they play. Once born, 
mammary development persists until puberty, during when extensive elongation of 
the ducts, accompanied by secondary branching, takes place. This provides a readily 
reachable system in which the study of branching morphogenesis is made feasible 
(Sakakura et al., 2013).  
 
During pregnancy, mammary glands undergo further development which 
have these striking features;  formation of tertiary branches, which end in alveolar 
buds and the quick proliferation of the luminal epithelium followed by subsequent 
differentiation and commitment to the secretory alveolar lineage (Forsmanl & 
Schwertfegerz, 2013) (Figure 1.2). A lactogenic key occurs during late pregnancy 
that is accompanied by the appearance of the milk proteins, whey acidic protein 
(WAP) and α-lactalbumin, and by the formation of lipid droplets (Barbieri, 2013; 
Kommagani et al., 2013). Following lactation, elimination of the now surplus 
alveolar cells is accomplished by cell death (apoptosis). Post-lactational 
deterioration, or involution, is the most remarkable example of physiologically 
regulated apoptosis in an adult tissue (Kommagani et al., 2013).  
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Figure 1.2 Schematic representation of various stages of mammary gland 
development (Forsmanl & Schwertfegerz, 2013). 
 
1.5  1-Methyl-1-Nitosourea (MNU) Induced Breast Cancer In Rats 
The use of animal models in the study of carcinogenesis is cardinal in 
investigating the mechanisms of carcinogenic interactions because the implicating 
agents can be clearly defined. The murine breast cancer model is a commonly used 
model for human breast cancer because of the similarities in hormonal dependence 
histopathological characteristics and the ease of tumour induction by the easily 
available  breast cancer-causing carcinogens such as 7,12-dimethylbenz[a] 
anthracene (DMBA) and 1-methyl-1-nitrosourea (MNU) (Imaoka et al., 2009; 
Medina, 2007; Nandi, 2006). Therefore, the two carcinogenic substances are 
considered good choices for the induction of cancers in most studies investigating 
mammary carcinogenesis and breast cancer therapeutics. 
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The features of MNU-induced and DMBA-induced models have been 
previously reviewed (Imaoka et al., 2014; Macejova & Brtko, 2001; Shirai et al., 
1997). They are alike in terms of reliability of tumour induction, organ site 
specificity and production of tumours with varying hormone responsiveness 
(Tsubura et al., 2011). Both provide the means for studying the attributes of tumour 
initiation, promotion and progression even though carcinomas induced by either 
carcinogen can rarely metastasize. 
 
In spite of such similarities, there are some notable differences that set these 
two murine breast cancer models apart. The MNU model is used for investigating 
mammary tumourigenesis induced by a direct acting carcinogen, whereas the DMBA 
model provides a platform for studying mammary tumorigenesis induced by a pre-
carcinogen requiring enzymatic-metabolic activation (Shirai et al., 1997). The MNU 
induced mammary carcinomas have a more aggressive histological pattern compared 
to those induced by DMBA and MNU-induced tumours have a higher incidence of 
adenocarcinomas (Medina, 2007). Furthermore, MNU-induced tumors appear to be 
more estrogen-dependent compared to DMBA-induced tumours which is more 
dependent prolactin for tumor progression (Medina, 2007). Since this study aims to 
examine the effects of both rapamycin and PF4 on the most ubiquitously prevalent 
human breast cancer, the MNU-induced murine breast cancer model is chosen for 
this study. 
 
The administration of MNU at a dose of 50 mg/kg body weight in rats aged 
21 days has been shown to be a rapid method for inducing mammary tumour with 
higher production of premalignant lesions including intraductal proliferations (IDP) 
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and ductal carcinoma in situ (DCIS) than other methods (Choudhuri et al., 2012; 
Nandi, 2006; Shirai et al., 1997). This latter feature has proved the model to be useful 
in studying breast cancer carcinogenesis at its earliest stage.  
 
The times to the first appearance of cancerous lesions are varied among the 
many types of pre-malignant and malignant lesions (Tsubura et al., 2011). For 
instance, IDP occurs 14 days post MNU induction, whilst the DCIS and 
adenocarcinomas appear 21 days post MNU-induction (Choudhuri et al., 2012). This 
model has been used widely as a preclinical in vivo model for evaluating the 
potential efficiency of an agent in breast cancer treatment. Again, based on these 
favourable characteristics, MNU-induced murine breast cancer model is deemed the 
most suitable model for  this study. 
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1.6 Programmed Cell-Death  
           Generally, programmed cell-death  (PCD) is the death of the cell in any types, 
it was determined by an intracellular program (Fuchs & Steller, 2011). PCD is 
confessed out in a structured process, which frequently intended superior during an 
organism's life-cycle (Ouyang et al., 2012). For example, the toes differentiation and 
fingers in an emerging human embryo occurs because cells between the 
fingers apoptose; the effect is that the digits are separate. PCD explores fundamental 
functions during both plant and metazoa (multicellular animals) tissue development 
(Walsh, 2014). Apoptosis and autophagy are both forms of programmed cell death, 
but necrosis is a non-physiological process that occurs as a result of infection or 
injury (Walsh, 2014). The other types of programme cell death were included 
cornification, mitotic catastrophe,  anoikis, excitotoxicity, paraptosis, pyroptosis, 
pyronecrosis and entosis (Kroemer et al., 2005).  
 
In 2005, the The Nomenclature Committee on Cell Death (NCCD) has 
formulated recommendations in the Cell Death and Differentiation (Kroemer et al., 
2005). The NCCD main function was provided the forum in describing the distinct 
modalities of cell death are critically evaluated and recommendations on their 
definition and use are formulated, hoping that a non-rigid, yet uniform, nomenclature 
will facilitate the communication among scientists and ultimately accelerate the pace 
of discovery. The NCCD also provided an updated guideline on the cell death study. 
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1.6.1 Necrosis 
‘Necrotic cell death’ or ‘necrosis’ is morphologically distinguished by an 
acquire in cell volume (oncosis), plasma membrane rupture, swelling of organelles 
and subsequent loss of intracellular contents. For years, necrosis have been 
considered simply as an accidental uncontrolled form of cell death, but facts are 
accumulating that the execution of necrotic cell death may be delicately modulated 
by a set of signal transduction pathways and catabolic mechanisms (Golstein & 
Kroemer, 2007). For instance, death domain receptors (e.g., TNFR1, Fas/CD95 and 
TRAIL-R) and Toll-like receptors (e.g., TLR3 and TLR4) have been shown to 
induce necrosis, in particular in the presence of caspase inhibitors. TNFR1-, 
Fas/CD95-, TRAILR- and TLR3-mediated cell death, seemingly depends on the 
kinase RIP1 (Mocarski et al., 2011) as this has been demonstrated by its 
knockout/knockdown and chemical inhibition with necrostatin-1 (Degterev et al., 
2013). Although there is no comprehensive agreement on the use of this expression, 
some researchers have suggested the term ‘necroptosis’ to specify regulated (as 
opposed to accidental) necrosis. At a biochemical level, necroptosis may be defined 
as a type of cell death that can be avoided by inhibiting RIP1 (either through genetic 
or pharmacological methods) (Ofengeim & Yuan, 2013) which may represent a 
convenient means to discriminate between programmed and fortuitous forms of 
necrosis. Thus far, however, there is no consensus on the biochemical changes that 
may be used to unequivocally identify necrosis. In the absence of a common 
biochemical denominator, necrotic cell death is still largely identified in negative 
terms by the absence of apoptotic or autophagic markers, in particular when the cells 
undergo early plasma membrane permeabilization (as compared with its delayed 
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occurrence, which is associated with late-stage apoptosis). For these reasons, caution 
should be used in classifying particular cell death routines as necrotic. 
 
1.6.2  Apoptosis 
Apoptosis or programmed cell death (PCD) is an active, energy-dependent 
process of cell death which occurs during development, in response to certain 
physiologic stimuli and secondary to cell injury and stress (Elmore, 2007; Gewies, 
2003; Giansanti et al., 2011).  The purpose of this type of cell death is for regulating 
the removal of damaged and unwanted cells in discrete tissues, a critical function in 
embryonic development and normal tissue homeostasis. It differs from necrotic cell 
death because the damaged cells are eliminated by PCD  in a fashion without 
eliciting intense inflammatory response (Ashkenazi & Salvesen, 2014). 
 
The term apoptosis had been coined in order to explain the morphological 
processes principal to controlled cellular self-destruction which was first discovered 
by Kerr, Wyllie and Currie (Czabotar et al., 2014).  Apoptosis is of Greek origin, 
meaning “falling off or dropping off”, in analogy to leaves falling off trees or petals 
dropping off flowers. This analogy emphasizes that the death of a living matter is an 
important and often a necessary part of the life cycle of any organism. 
 
 Apoptosis is an active and clearly-defined process which has monumentally 
contributed to multicellular organisms’s development and the regulation and 
preservation of the cell populations in tissues under physiological and pathological 
conditions. It should also be stressed that apoptosis is possibly the most common 
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form of programmed cell death, but other non apoptotic types of cell death  might 
also be of biological significance (Portt et al., 2011).  
 
Apoptosis is an orderly and tightly controlled series of events which 
culminates in coherent gene expression with specific proteomic signatures. It has a 
major function in normal growth and differentiation of organ systems and appears to 
be involved in a variety of human disorders (Delbridge et al., 2012). 
 
There are two gene families which are critical in the control of apoptosis;   
interleukin-1–converting enzyme (ICE) family of cysteine proteases (caspases) and 
proto-oncogene Bcl-2-related genes. Both of these families are homologous to cell 
death genes in Caenorhabditis elegans (C. elegans) (Potts & Cameron, 2011). 
Proteolytic activity plays a special role in many apoptotic systems, the ICE family 
being of special importance, since it seems to be central in Fas-mediated and tumor 
necrosis factor (TNF)-induced apoptosis (Azahri & Kavurma, 2013; Waters et al., 
2013).  
 
New evidence suggests that Bcl-2 protein has two different functions: 1) as 
an ion channel protein and 2) as an adaptor/docking protein through its binding to 
several other proteins which are important in modulating apoptosis (Bortner & 
Cidlowski, 2014). However, the precise way in which these proteins modulate 
apoptosis remains unclear and conflicting theories have been proposed. Further, the 
gene product of Bcl-2 does not prevent apoptosis under all conditions (e.g., does not 
protect target cells from apoptosis induced by cytotoxic T cells) (Bagci et al., 2006). 
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Finally, genes involved in cellular differentiation and proliferation are also important 
in modulating the apoptotic process (e.g., the c-Myc, the p53, and the apoptosis 
suppressor gene A20). Both c-Myc and p53 are incriminated in the induction of 
apoptosis under certain conditions, whereas A20 is a cytokine-induced primary 
response gene involved in the inhibition of the apoptotic process (Portt et al., 2011). 
 
1.7 Morphology And Biochemical Features 
Apoptotic cells can be recognized by distinct morphological changes such as 
cell shrinkage, cellular deformation with the loss of contact with its neighbouring 
cells (Figure 1.3). Apart from those above, apoptotic cell chromatin condenses and 
marginates to the nuclear membrane with plasma membrane blebbing or budding, 
before culminating in cellular fragmentation and  apoptotic bodies formation, a 
closely-compact membrane containing structure which is composed of cytosol, 
condensed chromatin, and organelles (Mariño et al., 2014). The apoptotic bodies are 
subsequently engulfed by macrophages and thus are removed from the tissue without 
causing an inflammatory response (Suzanne & Steller, 2013). 
 
Those morphological changes are a consequence of characteristic molecular 
and biochemical events occurring in an apoptotic cell, most particularly the 
activation of proteolytic enzymes which eventually mediate the cleavage of DNA 
into oligonucleosomal fragments as well as the cleavage of a multitude of specific 
protein substrates which usually determine the integrity and shape of the cytoplasm 
or organelles (Suzanne & Steller, 2013). Apoptosis is in contrast to necrosis in which 
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the cells suffer a major insult, resulting in a loss of membrane integrity, swelling and 
disruption of the cells. During necrosis, the cellular contents are uncontrollably  
released  into the cell's microenvironment,  resulting in severe damage to the 
surrounding cells and a strong inflammatory response by the necrotic tissues (Table 
1.1) (Nanji & Hiller-Sturmhöfel, 1997).   
 
Table 1.1 Differential features of apoptosis and necrosis. 
Differential features of apoptosis and necrosis 
Apoptosis Necrosis 
Affects single cell 
Affects groups of 
neighboring cells 
No inflammatory response 
Significant inflammatory 
response 
Cell shrinkage Cell swelling 
Membrane blebbing with maintained cellular integrity  
Loss of membrane 
integrity 
Increased mitochondria membrane permeability release 
of proapoptotic protein and formation of apoptotic 
bodies 
Organelle swelling and 
lysosomal leakage 
Chromatin condensation and non-random DNA 
fragmentation 
Random degradation of 
DNA 
Apoptotic bodies ingested by neighboring cells 
Lysed cell ingested by 
macrophage. 
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Figure 1.3 Morphological comparisons between apoptotic and necrotic cell deaths. 
Key features of apoptosis that includes cellular shrinking, chromatin condensation 
and margination at the nuclear periphery with the eventual formation of membrane-
bound apoptotic bodies, comprising organelles, cytosol and nuclear fragments that 
are subsequently phagocytosed without triggering inflammatory processes. On the 
contrary, the necrotic cell swells and becomes leaky with the eventual disruption of 
membrane which results in the release of cellular contents into the surrounding 
tissue, triggering inflammation (Nanji & Hiller-Sturmhöfel, 1997). 
 
Apoptotic cells usually display a distinctive constellation of biochemical 
modifications that underlie the structural pathology. Some of these features are 
shared by necrotic cells as well, but other alterations are more necrosis-specific. 
Caspases cleavage of the nuclear scaffold and cytoskeletal proteins (together with 
protein cross-linking) underlies the distinctive nuclear and cytoplasmic structural 
alterations solely seen in apoptotic cells. Caspase activity also triggers endonucleases 
(Ashkenazi & Salvesen, 2014). 
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Extensive protein cross-linking by transglutaminase activation converts 
cytoplasmic proteins into covalently linked shrunken shells that may break into 
apoptotic bodies (Szondy et al., 2011). Apoptotic cells demonstrates a characteristic 
feature of DNA break into large 50-kilobase to 300-kilobase pieces. Subsequently, 
there is internucleosomal cleavage of DNA into oligonucleosomes in multiples of 
180 to 200 base pairs by Ca
2+
- and Mg
2+
- dependent endonucleases (Bortner et al., 
1995). The fragments are visualizable by agarose gel electrophoresis as DNA 
ladders. Endonuclease activity also forms the basis for detecting cell death by 
cytochemical techniques that recognize the double-stranded DNA breaks. However, 
internucleosomal DNA cleavage is not specific for apoptosis (Nagata, 2000). 
Moreover, the “smear” pattern of DNA fragmentation thought to be indicative of 
necrosis may only be a late autolytic phenomenon, and typical DNA ladders can also 
be seen in necrotic cells as well (Widlak & Garrard, 2009). 
 
Apoptotic cells have phosphatidylserine in the outer layers of their plasma 
membranes, the phospholipids having been “flipped” out from the inner layers. In 
some types of apoptosis, thrombospondin, an adhesive glycoprotein, is also 
expressed on the surfaces of apoptotic bodies (Hengartner, 2001). These alterations 
let the early detection of the dead cells by macrophages and adjacent cells for 
phagocytosis, without the discharge of proinflammatory cellular components. In this 
way, the apoptotic response disposes undesirable cells with minimal compromise to 
the surrounding tissue. 
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1.7.1 Mechanism Of Apoptosis Pathway 
The apoptosis mechanisms are extremely multifarious and complicated, 
linking each key player into an energy-dependent cascade of molecular events 
(Figure 1.4). Currently, research shows that there are two main apoptotic pathways: 
the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway 
(Wong, 2011). Nevertheless, it is now verified that the two pathways are mutually 
linked and that a principal regulator in one pathway can also play a major part in the 
other pathway (Bagci et al., 2006; Prehn et al., 2013). Besides these two, there is also 
another pathway that involves T-cell mediated cytotoxicity and perforin-granzyme-
dependent killing of the cells.  
 
The perforin/granzyme pathway can induce apoptosis via either granzyme B 
or granzyme A. The extrinsic, intrinsic, and granzyme B pathways eventually 
converge on the same terminal apoptotic event in the form an execution pathway. 
This pathway is initiated by the cleavage of caspase-3 which leads to DNA 
fragmentation, degradation of cytoskeletal and nuclear proteins, cross-linking of 
proteins, formation of apoptotic bodies, expression of ligands for phagocytic cell 
receptors and finally uptake by phagocytic cells. The granzyme A pathway activates 
a parallel, caspase-independent cell death pathway via single stranded DNA damage 
(Martinvalet et al., 2005). 
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Figure 1.4  Schematic representation of apoptotic events (Dabbah & Rajei, 2013). 
 
The major pathways of apoptosis are extrinsic and intrinsic as well as a 
perforin/granzyme pathway. Every pathway requires particular triggering signals to 
initiate an energy-dependent cascade of molecular events. Every pathway activates 
its own initiator caspase (8, 9, 10) which in turn will activate the executioner 
caspase-3. On the opposite, granzyme A pathway is executed in a caspase-
independent style. The execution pathway results in typical cytomorphological 
features including cell shrinkage, chromatin condensation, formation of cytoplasmic 
blebs and apoptotic bodies and finally phagocytosis of the apoptotic bodies by 
adjacent parenchymal cells, neoplastic cells or macrophages (Ashkenazi & Salvesen, 
2014). 
Cytochrome C 
Nucleus 
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1.7.1.1 Extrinsic Pathway (Death receptor) 
  The extrinsic pathways of apoptosis involve transmembrane ligand-
death receptor interactions. These death receptors are genetically belonged to 
the tumour necrosis factor (TNF) receptor gene superfamily members 
(Hengartner, 2001; Wang et al., 2012).  TNF receptor family members share 
similar cysteine-rich extracellular domains and have a cytoplasmic domain of 
about 80 amino acids known as death domain (Aggarwal et al., 2012). This 
death domain plays an important role in transmitting the death signal from the 
cell surface to the intracellular signaling pathways. Among the best-
characterized ligands and their corresponding death receptors include fatty acid 
synthetase ligand (FasL) / fatty acid synthetase receptor (FasR), Tumour 
necrosis factor alpha (TNF-α) / type 1 TNF receptor (TNFR1), Apo3 ligand 
(Apo3L) / Death receptor 3 (DR3), Apo2 ligand (Apo2L) /DR4 and 
Apo2L/DR5 (Dickens et al., 2012). 
 
The sequences of events that describe the extrinsic pathway of apoptosis 
are best illustrated with the FasL/FasR and TNF-α/TNFR1 models (Rubio-
Moscardo et al., 2005). In these models, there is a clustering of receptors when 
homologous trimeric ligands bind to them. Cytoplasmic adapter proteins are 
then recruited after successful binding, which possess corresponding death 
domains that bind with the death receptors. Accordingly, the binding of Fas 
ligand to Fas receptor to the adapter protein Fas-associated death domain 
(FADD) and the binding of TNF ligand to TNF receptor results in the binding 
of the adapter protein  TNF receptor-associated death domain (TRADD) with 
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recruitment of FADD and RIP (Schneider & Tschopp, 2000). FADD then 
associates with procaspase-8 via dimerization of the death effector domain. At 
this stage, a death-inducing signaling complex (DISC) is produced, an essential 
component in the auto-catalysis of procaspase-8 (Kischkel et al., 1995). 
 
Once caspase-8 is activated, the execution phase of apoptosis is thus 
activated. Death receptor-mediated apoptosis can be inhibited by a protein 
called c-FLIP which will bind to FADD and caspase-8, rendering them 
ineffective (Chang et al., 2002; Scaffidi et al.,1999). Another potential target for 
apoptosis inhibition involves a protein called Toso, which has been shown to 
block Fas-induced apoptosis in T cells via inhibition of caspase-8 processing 
(Hitoshi et al., 1998; Song & Jacob, 2005). 
 
1.7.1.2 Intrinsic Pathway (Mitochondrial-dependent pathway) 
The intrinsic pathway is regulated at the mitochondrial level and 
responsive to both extracellular stimuli and internal insults such as DNA 
damages (Elumalai et al., 2012). This pathway is set off via alterations in 
mitochondrial membrane potential and increased permeability of the membrane, 
resulting in the leakage of cytochrome c, a protein important to mitochondrial 
respiration. In the cytosol, cytochrome c binds to apoptosis activating factor 
(Apaf-1) to form a complex known as apoptosome, which in turn activates 
caspase-9 (Rogalska et al., 2013). At this juncture, if the balance between pro-
apoptotic and inhibitory control is tipped in favor of cell death, the caspase 
cascade is initiated resulting in the withering of the cells (Tait & Green, 2010).  
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1.8  Bcl-2 Family 
The Bcl-2 family proteins play a critical role in apoptosis regulation 
(Shamas-Din et al., 2013). Changes in the levels or bioactivities of these 
proteins are necessary for diverse  physiological processes where programmed 
cell death are required for the maintenance and maturation of normal anatomical 
and physiological development such as during fetal growth, haematopoietic and 
immune cell differentiation, oogenesis, mammary gland involution and normal 
cell turnover in the epidermis, gut and other tissues (Carson & Ribeiro, 1993; 
Chipuk et al., 2010; Kerr et al., 1972). Moreover, pathological alterations in the 
expression of Bcl-2 proteins family have been identified as one of the main 
culprits in carcinogenesis, autoimmunity, immunodeficiency, heart failure, 
stroke and other pathologies (Favaloro et al., 2012; Kelly & Strasser, 2011; 
Nagata, 2010; Papathanasiou et al., 2012). Consequently, methods for assessing 
the relative levels and bioactivities of Bcl-2 proteins family are extremely 
important to scientists in a broad range of disciplines.  
 
The Bcl-2 oncoprotein is an inhibitor of apoptotic cell death (Ola et al., 
2011). Many experiments which involve cells that are genetically transfected 
with Bcl-2 mutations have shown that elevated levels of this protein can protect 
a wide variety of cells from various cell death stimuli ranging from growth 
factor withdrawal and cytotoxic lymphokines to virus infection and DNA-
damaging, anticancer drugs and radiation (Fuchs & Steller, 2011). The 26-kD 
Bcl-2 resides on the cytoplasmic surface of the mitochondrial outer membrane, 
